GPRC5D and neoplasm: Another study reported the development of novel NK-CAR with dual targeting capacity against BCMA and GPRC5D; dual BCM5A/GPRC5D dual-targeted CAR-NK cells improved animal survival and reduced tumor relapse compared to single-targeting CAR-NK cells [74].